• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

导管原位癌降期和升期的研究范式:手术治疗综述

Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review.

作者信息

Orsaria P, Granai A V, Venditti D, Petrella G, Buonomo O

机构信息

Division of Surgical Oncology, Department of Surgery, Tor Vergata University Hospital, 00133 Rome, Italy.

出版信息

Int J Surg Oncol. 2012;2012:560493. doi: 10.1155/2012/560493. Epub 2012 May 16.

DOI:10.1155/2012/560493
PMID:22666571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3362033/
Abstract

Counseling patients with DCIS in a rational manner can be extremely difficult when the range of treatment criteria results in diverse and confusing clinical recommendations. Surgeons need tools that quantify measurable prognostic factors to be used in conjunction with clinical experience for the complex decision-making process. Combination of statistically significant tumor recurrence predictors and lesion parameters obtained after initial excision suggests that patients with DCIS can be stratified into specific subsets allowing a scientifically based discussion. The goal is to choose the treatment regimen that will significantly benefit each patient group without subjecting the patients to unnecessary risks. Exploring the effectiveness of complete excision may offer a starting place in a new way of reasoning and conceiving surgical modalities in terms of "downscoring" or "upscoring" patient risk, perhaps changing clinical approach. Reexcison may lower the specific subsets' score and improve local recurrence-free survival also by revealing a larger tumor size, a higher nuclear grade, or an involved margin and so suggesting the best management. It seems, that the key could be identifying significant relapse predictive factors, according to validated risk investigation models, whose value is modifiable by the surgical approach which avails of different diagnostic and therapeutic potentials to be optimal. Certainly DCIS clinical question cannot have a single curative mode due to heterogeneity of pathological lesions and histologic classification.

摘要

当治疗标准的范围导致多样且令人困惑的临床建议时,以合理的方式为导管原位癌(DCIS)患者提供咨询可能极其困难。外科医生需要能够量化可测量的预后因素的工具,以便在复杂的决策过程中结合临床经验使用。具有统计学意义的肿瘤复发预测因素与初次切除后获得的病变参数相结合,表明DCIS患者可以被分层到特定亚组,从而进行基于科学的讨论。目标是选择能使每个患者组显著受益且不会让患者承受不必要风险的治疗方案。探索完全切除的有效性可能为一种新的推理方式和构想手术方式提供一个起点,即根据患者风险的“降分”或“加分”来进行,这可能会改变临床方法。再次切除也可能通过揭示更大的肿瘤大小、更高的核分级或切缘受累情况来降低特定亚组的评分,并提高局部无复发生存率,从而提示最佳的治疗管理。似乎关键在于根据经过验证的风险调查模型识别出显著的复发预测因素,其价值可通过利用不同诊断和治疗潜力以达到最佳效果的手术方法来改变。当然,由于病理病变和组织学分类的异质性,DCIS的临床问题不可能有一种单一的治愈模式。

相似文献

1
Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review.导管原位癌降期和升期的研究范式:手术治疗综述
Int J Surg Oncol. 2012;2012:560493. doi: 10.1155/2012/560493. Epub 2012 May 16.
2
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.应用USC/范纽斯预后指数的259例乳腺导管原位癌患者:长期随访的回顾性研究
Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9.
3
Predictors of local recurrence following excision alone for ductal carcinoma in situ.导管原位癌单纯切除术后局部复发的预测因素。
Cancer. 1999 Jan 15;85(2):427-31.
4
Ductal Carcinoma In Situ - Quo Vadis?导管原位癌——路在何方?
Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S5-S6.
5
Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal carcinoma .超声深度学习影像组学和临床机器学习模型预测纯导管癌的低核分级、雌激素受体、孕激素受体和人表皮生长因子受体2受体状态
Gland Surg. 2024 Apr 29;13(4):512-527. doi: 10.21037/gs-23-417. Epub 2024 Apr 11.
6
Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies.导管原位癌。保乳治疗的成功:两项单机构非随机前瞻性研究的共同经验。
Surg Oncol Clin N Am. 1997 Apr;6(2):385-92.
7
The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast.乳腺肿块切除边缘评估作为乳腺导管原位癌残余肿瘤负荷预测指标的价值。
Cancer. 2002 Apr 1;94(7):1917-24. doi: 10.1002/cncr.10460.
8
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
9
Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy.乳房导管原位癌保乳手术及放疗的病理与技术考量
Ann Oncol. 1999 Aug;10(8):883-90. doi: 10.1023/a:1008339113607.
10
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析:基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.

引用本文的文献

1
Contrast-Enhanced Mammographic Features of In Situ and Invasive Ductal Carcinoma Manifesting Microcalcifications Only: Help to Predict Underestimation?仅表现为微钙化的原位及浸润性导管癌的对比增强乳腺X线特征:有助于预测低估情况吗?
Cancers (Basel). 2021 Aug 30;13(17):4371. doi: 10.3390/cancers13174371.
2
Ductal Carcinoma In Situ Underestimation of Microcalcifications Only by Stereotactic Vacuum-Assisted Breast Biopsy: A New Predictor of Specimens without Microcalcifications.仅通过立体定位真空辅助乳腺活检对导管原位癌微钙化的低估:无微钙化标本的新预测指标
J Clin Med. 2020 Sep 17;9(9):2999. doi: 10.3390/jcm9092999.
3
Predictive factors for invasive cancer in surgical specimens following an initial diagnosis of ductal carcinoma in situ after stereotactic vacuum-assisted breast biopsy in microcalcification-only lesions.在仅存在微钙化的病变中,经立体定位真空辅助乳腺活检初步诊断为导管原位癌后,手术标本中浸润性癌的预测因素。
Diagn Interv Radiol. 2016 Jan-Feb;22(1):29-34. doi: 10.5152/dir.2015.14453.

本文引用的文献

1
Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194.保乳手术联合放疗治疗导管原位癌:与 ECOG 研究 5194 的比较
Cancer. 2011 Mar 15;117(6):1156-62. doi: 10.1002/cncr.25623. Epub 2010 Nov 29.
2
Ductal carcinoma in-situ: an update for clinical practice.导管原位癌:临床实践的最新进展。
Surg Oncol. 2011 Mar;20(1):e23-31. doi: 10.1016/j.suronc.2010.08.007. Epub 2010 Nov 24.
3
Local control of ductal carcinoma in situ based on tumor and patient characteristics: the surgeon's perspective.基于肿瘤和患者特征的导管原位癌局部控制:外科医生的观点。
J Natl Cancer Inst Monogr. 2010;2010(41):152-7. doi: 10.1093/jncimonographs/lgq018.
4
Epidemiology of ductal carcinoma in situ.导管原位癌的流行病学
J Natl Cancer Inst Monogr. 2010;2010(41):139-41. doi: 10.1093/jncimonographs/lgq027.
5
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.保乳手术治疗导管原位癌后局部复发风险的列线图预测。
J Clin Oncol. 2010 Aug 10;28(23):3762-9. doi: 10.1200/JCO.2009.26.8847. Epub 2010 Jul 12.
6
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.乳腺导管原位癌:发病率、治疗和结局的系统评价。
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
7
Pathological classification of DCIS and planning of therapeutic management.导管原位癌的病理分类及治疗管理规划
Anticancer Res. 2009 May;29(5):1499-506.
8
Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience.保乳手术联合或不联合放疗与乳房切除术治疗导管原位癌:法国的调查经验
Br J Cancer. 2009 Apr 7;100(7):1048-54. doi: 10.1038/sj.bjc.6604968. Epub 2009 Mar 10.
9
Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ.乳腺导管原位癌保乳及放疗后切缘状态对局部复发的影响。
J Clin Oncol. 2009 Apr 1;27(10):1615-20. doi: 10.1200/JCO.2008.17.5182. Epub 2009 Mar 2.
10
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.导管原位癌与乳腺癌演进过程中的异质性出现。
Clin Cancer Res. 2008 Jan 15;14(2):370-8. doi: 10.1158/1078-0432.CCR-07-1127.